Targeting IL-17A to combat immune-related adverse events.

Sierra-Davidson K, Boland GM

DOI: 10.1038/s43018-024-00804-2
Published: 2024 Sep
Container: Nature cancer
Publisher: Not recorded
Open access: unknown

Credibility signals

limited evidence Score 43/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

cautionDOI registered: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
cautionDOI resolves: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility. Source: DOAJ; license: CC0
not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredROR affiliation: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredOpen access status: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication license: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication version: A publication version was supplied but is not scored. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer

Cite this work

BibTeX

@article{allodium:10.1038/s43018-024-00804-2,
  title = {Targeting IL-17A to combat immune-related adverse events.},
  author = {Sierra-Davidson K and Boland GM},
  year = {2024},
  journal = {Nature cancer},
  doi = {10.1038/s43018-024-00804-2},
  url = {https://doi.org/10.1038/s43018-024-00804-2}
}

RIS

TY  - JOUR
TI  - Targeting IL-17A to combat immune-related adverse events.
AU  - Sierra-Davidson K
AU  - Boland GM
PY  - 2024
JO  - Nature cancer
DO  - 10.1038/s43018-024-00804-2
UR  - https://doi.org/10.1038/s43018-024-00804-2
ER  -

APA

K, S., & GM, B. (2024). Targeting IL-17A to combat immune-related adverse events.. Nature cancer. https://doi.org/10.1038/s43018-024-00804-2

Source records

pubmed · retrieved 2026-09-26T06:46:04.333Z